SCHEMBL4243154

SCHEMBL4243154

COC(=O)c1ccc2[nH]c(CCO[Si](C)(C)C(C)(C)C)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
PKM P14618 2/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HTT P42858 2/20 0.42
RAB9A P51151 4/20 0.40
NPC1 O15118 2/20 0.40
CREBBP Q92793 1/20 0.40
THRB P10828 1/20 0.40
PSMB8 P28062 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
KIF11 P52732 1/20 0.39
RHEB Q15382 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241794 0.89 SMN1; SMN2 (0.53) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL15294555 0.81 SMN1; SMN2 (0.53) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL8906504 0.81 L3MBTL1 (0.54) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL4241835 0.79 RHEB (0.38) MAPTALDH1A1RAB9ANPC1MEN1
SCHEMBL8632161 0.79 MAPT (0.55) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL4241828 0.78 CYP2C9 (0.35) MAPTALDH1A1HTTMEN1KMT2A
SCHEMBL22533987 0.78 SMN1; SMN2 (0.55) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL6093891 0.77 SMN1; SMN2 (0.57) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL4246402 0.77 SMN1; SMN2 (0.54) MAPTPKMGAASMN1; SMN2MAPK1
SCHEMBL4798414 0.77 NPSR1 (0.46) MAPTSMN1; SMN2MAPK1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
EP-1993536-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SmithKline Beecham Corporation (US) 2008-11-26 EP disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed
WO-2007103755-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249599-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 MAPT 1769/4885PKM 3210/4885GAA 766/4885
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA MAPT 2228/4885PKM 539/4885GAA 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.